Clinical Trial Update: Tucatinib, Trastuzumab, and Capecitabine With SRS for Brain Metastases From HER-2 Positive Breast Cancer [Phase 1]

View source ↗

Summary

A Phase 1 trial evaluating tucatinib, trastuzumab, and capecitabine with stereotactic radiosurgery for brain metastases in HER2-positive breast cancer was termi…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Brain Metastases
• Breast Cancer

Drugs mentioned

• Capecitabine (capecitabine)
• Trastuzumab (trastuzumab)
• Tucatinib (tucatinib)

Snippet

Sponsor: Baptist Health South Florida | Conditions: Brain Metastases, HER2-positive Breast Cancer | Phase 1 | Status: TERMINATED